GSK962040 Drug-drug Interaction Study With Ketoconazole

Summary

This study will determine the effect of 400 mg ketoconazole on the pharmacokinetics of a single dose of GSK962040. The results from this study will help to estimate the maximum increase in exposure during concomitant use of strong CYP3A4 inhibitors. This study will also contain an exploratory investigation of biliary secretion of GSK962040 and or its metabolites.

Timeline

Start

2009-09-18

Primary completion

2009-11-30

Completion

2009-11-30

Drugs

Indications